Merck said it closed the underwritten public offering of 7 series of notes, including Floating Rate Notes due 2028, 4.300% Notes due 2028, 4.650% Notes due 2031, 4.950% Notes due 2033, 5.200% Notes due 2036, 5.750% Notes due 2046 and 5.850% Notes due 2056, on May 22, 2026.

1. 01

   Merck said it closed the underwritten public offering of 7 series of notes, including Floating Rate Notes due 2028, 4.300% Notes due 2028, 4.650% Notes due 2031, 4.950% Notes due 2033, 5.200% Notes due 2036, 5.750% Notes due 2046 and 5.850% Notes due 2056, on May 22, 2026.

2. 02

   The company issued Floating Rate Notes totaling $500,000,000 and 4.300% Notes due 2028 totaling $1,000,000,000 in principal amount.

3. 03

   The company issued 4.650% Notes due 2031 totaling $500,000,000, 4.950% Notes due 2033 totaling $1,000,000,000 and 5.200% Notes due 2036 totaling $1,500,000,000 in aggregate principal amount.

4. 04

   Merck issued 5.750% Notes due 2046 totaling $500,000,000 and 5.850% Notes due 2056 totaling $1,000,000,000. The notes were issued under an indenture dated January 6, 2010 with U.S. Bank Trust National Association as trustee.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.